In the United States, azelaic acid used in a rinse-off body scrub at 5–10% concentration is regulated as a cosmetic ingredient under the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the FDA, provided the product's label and marketing claims stay within cosmetic boundaries. Cosmetic claims describe how a product affects the appearance of the body — brightening, smoothing, exfoliating, evening skin tone — and do not make therapeutic or disease-treatment claims. The moment a brand makes a claim like 'treats acne,' 'reduces rosacea redness,' or 'clinically proven to clear hyperpigmentation caused by acne,' the product may be regulated as an OTC drug, which triggers substantially higher manufacturing, testing, and labeling requirements under 21 CFR Part 333 or Part 352 depending on the claimed condition.
Azelaic acid does not appear on the FDA's approved OTC drug monograph list in the US at cosmetic-level concentrations, but the FDA regulates claims, not just concentrations. This means a 5% azelaic acid scrub sold with acne-treatment claims is treated as a drug, while an identical formula sold as an exfoliating brightening scrub is treated as a cosmetic. The practical implication: work with a regulatory consultant to review all label text, website copy, and social media claims before launch.
Under the Modernization of Cosmetics Regulation Act (MoCRA), signed in December 2022, FDA is implementing new rules through 2025–2026 including mandatory facility registration, product listing with FDA, good manufacturing practice regulations for cosmetics, and new substantiation requirements for safety data. Brands and manufacturers must track these rollout dates as they affect both importer and manufacturer obligations.
In the European Union, azelaic acid is an approved cosmetic ingredient with no specific restriction listed in Annex II (prohibited substances), Annex III (restricted substances), or Annexes IV–VI (colorants, preservatives, UV filters) of EU Cosmetics Regulation EC 1223/2009. This means it can be used freely at levels justified by the product's safety assessment. However, every cosmetic product placed on the EU market must have a Product Information File (PIF) containing: a cosmetic product safety report signed by a qualified safety assessor, a description of the manufacturing method, a declaration of GMP compliance, and evidence of the claimed effect where any efficacy claim is made.
EU claim regulations (EC 655/2013 and the associated technical document) prohibit misleading or exaggerated claims. Terms like 'clinically proven' require supporting clinical or consumer study data that is proportionate to the claim. The Cosmetic Products Notification Portal (CPNP) submission is required before the product is placed on the EU market, handled by your designated EU Responsible Person.
For the UK post-Brexit, parallel requirements apply via the UK's Office for Product Safety and Standards (OPSS) portal. The UK maintains its own product notification system and requires a UK Responsible Person. REACH regulation considerations apply if your formula uses substances that are pre-registered under UK REACH, though most cosmetic-grade azelaic acid is already registered.
AJ Cosmo Labs connects founders with manufacturers and regulatory consultants who have EU and UK compliance experience, helping you navigate notification requirements without building that expertise in-house from scratch.
Ingredients in this answer: Azelaic Acid
Read the full guide on Private Label Azelaic Acid Body Scrub Manufacturer Low MOQ →